Gut microbiota and prebiotics in Parkinson's disease: The RESISTA-PD Trial

Andreas SchwiertzProf. Andreas Schwiertz, Institute of Microecology, Germany will present his latest research during Targeting Microbiota 2023 on October 17-19 in a talk titled "Gut microbiota and prebiotics in Parkinson's disease: The RESISTA-PD Trial".

The composition of the gut microbiome is linked to multiple diseases, including Parkinson’s disease (PD). Bacteria producing short-chain fatty acids (SCFAs) and fecal SCFA concentrations are reduced in PD. SCFAs exert various beneficial functions in humans. In the interventional, monocentric, open-label clinical trial RESISTA-PD Prof. Schwiertz and his colleagues aimed at altering fecal SCFAs by an 8-week prebiotic intervention with resistant starch (RS).

In the PD + RS group, fecal butyrate concentrations increased significantly, and fecal calprotectin concentrations dropped significantly.  Clinically, Prof. Schwiertz and his team observed a reduction in non-motor symptom load in the PD+RS group.

About Prof. Prof. Schwiertz

Dr. Andreas Schwiertz is a microbiologist and molecular biologist. He trained at the Carl von Ossietzky University, Oldenburg (GER), the University College Cork (IRL) and Sate University of St. Petersburg (RUS). He received his PhD from the University of Potsdam (GER), where he trained under Prof. Michael Blaut in human gastrointestinal microbiology and on probiotics. In 2012 he received his lecturer qualification from the Justus Liebig University of Giessen on gastrointestinal microbiology where he is associated professor. In 2003 he joined the Institute of Microecology in Herborn, where he serves currently as CEO and CSO.

Join Targeting Microbiota 2023 to learn more about Prof. Schwiertz's talk. You can learn more about Targeting Microbiota 2023 program here.

Targeting Microbiota 2023 Congress
October 17-19, 2023 - Venice
Linkedin | Facebook | Website

Microbiota in the Press & Media

  • 1
  • 2
  • 3
Prev Next